Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program

 Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program

Takeda Signs a Licensing Option Agreement with Emendo Biotherapeutics for its OMNI Nuclease Program

Shots:

  • Emendo to receive convertible notes from Takeda Ventures, will convert it into SeriesB funding utilizing it to advance its gene editing discovery platform & biotherapies into clinical trials. Takeda to get an option to utilize Emendo’s OMNI nuclease program in editing of two genes
  • Emendo will also utilize its gene editing platform to optimize the OMNI nuclease for Takeda’s targeted genes
  • OMNI nuclease is a gene editing program which optimizes per target sequence to develop therapies for genetic diseases by specifically editing a gene

Click here to read full press release/ article | Ref: PRNewwire | Image: PRISM

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post